$KTOV “Merck's Keytruda Approved For Skin Cancer Merck & Co., Inc. (NYSE:MRK) said the FDA as approved Keytruda, its anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.” Didn’t mention KTOV’s wonderful drug? Why?
  • 2
2 Likes